Wearable tech – the new golden ticket for patient adherence?
Wearable technology is being credited with increasing patient adherence, easing implementation of treatments, and creating Real World Evidence that can be used for Payer and HTA negotiations. But what's actually stopping companies from using it?
The report details the findings from conversations with 10 of the world’s leading experts and explores several case studies giving you the latest insights into the applications and outcomes of using wearable tech. Find out exactly what you need to know about how wearable tech is developing and ensure you are prepared for the next five years.
“I see wearables for a pharma company as a means to get to better treatment for patients, but also it needs to happen in a collaborative way with all the different stakeholders in the eco system.Pharma cannot own that. That’s not our role.”
Erik Janssen, Vice President Global New Patient Solutions Neurology at UCB
FirstWord interviewed 10 experts from the US and Europe. Respondents have between 5 and 30 years’ experience working in a variety of organisations, including:
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Wearable tech – the new golden ticket for patient adherence?
Wearable technology is being credited with increasing patient adherence, easing implementation of treatments, and creating Real World Evidence that can be used for Payer and HTA negotiations. But what's actually stopping companies from using it?
The report details the findings from conversations with 10 of the world’s leading experts and explores several case studies giving you the latest insights into the applications and outcomes of using wearable tech. Find out exactly what you need to know about how wearable tech is developing and ensure you are prepared for the next five years.
“I see wearables for a pharma company as a means to get to better treatment for patients, but also it needs to happen in a collaborative way with all the different stakeholders in the eco system.Pharma cannot own that. That’s not our role.”
Erik Janssen, Vice President Global New Patient Solutions Neurology at UCB
FirstWord interviewed 10 experts from the US and Europe. Respondents have between 5 and 30 years’ experience working in a variety of organisations, including:
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved